StreetInsider.com News Articles

Form EFFECT Biodexa Pharmaceuticals

Thu, 01 Oct 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20261001/27131012.html

Form F-1 Biodexa Pharmaceuticals

Thu, 24 Sep 2026 09:01:00 -0400

si-local-file:///var/storage/secattach/20260924/27099743.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061782.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061783.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061784.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061785.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061786.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061787.html

Form 424B3 Biodexa Pharmaceuticals

Tue, 15 Sep 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260915/27061788.html

Form 6-K Biodexa Pharmaceuticals For: Sep 15

Tue, 15 Sep 2026 08:27:00 -0400

si-local-file:///var/storage/secattach/20260915/27061643.html

Biodexa raises $2.3M via warrant exercise agreement

Tue, 15 Sep 2026 08:03:46 -0400

Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) has entered into a warrant exercise agreement with an existing accredited investor, generating approximately $2.3 million in gross proceeds before financial advisor fees and other transaction expenses, according to a press release.

Under the terms of the agreement, the investor exercised outstanding warrants to purchase 2,204,218 American Depositary Shares at an exercise price of $1.05 per share. The ADSs issued upon exercise were registered under an effective registration statement on Form F-1.

In exchange for the immediate cash exercise of the existing warrants, the investor will receive new unregistered warrants to purchase up to 4,408,436 ADSs. The

Biodexa raises $2.3M via warrant exercise agreement

Tue, 15 Sep 2026 08:03:46 -0400

In exchange for the immediate cash exercise of the existing warrants, the investor will receive new unregistered warrants to purchase up to 4,408,436 ADSs. The

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

Tue, 15 Sep 2026 08:00:00 -0400

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

September 15, 2026

Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,204,218 American Depositary Shares (“ADSs”) of the Company (the “Existing Warrants”) at an exercise price of $1.05 for gross cash proceeds of approximately $2.3 million, before deducting financial

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

Tue, 15 Sep 2026 08:00:00 -0400

Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds

September 15, 2026

Form 424B3 Biodexa Pharmaceuticals